Davis Blaine's Insider Trades & SAST Disclosures
Davis Blaine's most recent trade in Cartesian Therapeutics Inc was a trade of 4,028 Common Stock done at an average price of $16.8 . Disclosure was reported to the exchange on Jan. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Davis Blaine.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Cartesian Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 03 Jan 2025 | 4,028 | 94,811 (0%) | 0% | 16.8 | 67,800 | Common Stock |
|
Cartesian Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.72 per share. | 03 Jan 2025 | 3,961 | 98,839 (0%) | 0% | 16.7 | 66,235 | Common Stock |
|
Cartesian Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,600 | 64,600 | - | - | Employee Stock Option (right to buy) | |
|
Cartesian Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 22,000 | 102,800 (0%) | 0% | 0 | Common Stock | |
|
Selecta Biosciences Inc
|
Davis Blaine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,110,000 | 3,110,000 | - | - | Employee Stock Option (right to buy) | |
|
Selecta Biosciences Inc
|
Davis Blaine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 2,424,000 | 2,424,000 (2%) | 2% | 0 | Common Stock | |
|
Selecta Biosciences Inc
|
Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Nov 2022 | 1,250,000 | 1,250,000 | - | - | Employee Stock Option (right to buy) | |
|
Protara Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.13 per share. | 15 Jul 2022 | 5,081 | 20,662 (0%) | 0% | 3.1 | 15,904 | Common Stock |
|
Protara Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 84,800 | 84,800 | - | - | Stock Option (Right to Buy) | |
|
Protara Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 14,100 | 15,581 (0%) | 0% | 0 | Common Stock | |
|
Protara Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
|
Protara Therapeutics Inc
|
Blaine Davis | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 16.91 per share. | 22 Sep 2020 | 1,481 | 1,481 (0%) | 0% | 16.9 | 25,038 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges